Swiss rare disease specialist VectivBio Holding AG is taking over US biotech Comet Therapeutics Inc. for an undisclosed amount. Comet focusses on treatments for metabolic diseases.
With new backing from large pharma, rising investors interest, and new incubators on stage, the AMR community is now urging policy makers worldwide to bring pull incentives into reality.
ADC Therapeutics is set to receive up to US$325m for a royalty share in its antibody drug conjugates Zynlonta and Cami.
Cardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
GSK-partnered Merck is throwing in the towel for a Phase II trial of its immunotherapy contender bintrafusp alfa after disappointing results.
UK-based start-up Beckley Psytech has completed an upsized Series B financing, raising €68m (US$80m). Proceeds will go towards the companys pipeline of psychedelic compounds dedicated to addressing neurological and psychiatric disorders.
ERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Setback for CureVac: Boehringer Ingelheim halts a 7-year-old €500m lung cancer collaboration with the Tübingen-based biopharmaceutical company.
Vaccine maker Valneva SE announced the initiation of a further Phase III trial for its COVID-19 vaccine candidate VLA2001.
Visus Therapeutics has baged a €20m stock financing to advance development of Brimochol for presbyopia